-

02:11:50 AM

SLRX Stock News

SLRX - Salarius Pharmaceuticals Inc

01/27/23 8:30 AM

Nasdaq : SLRX

clinical triallow float

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better performance than standard-of-care treatment Company plans to submit an Investigational New Drug application to the U.S. Food and Drug

RHEA-AI

neutral

01/19/23 8:30 AM

Nasdaq : SLRX

conferencesclinical triallow float

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

RHEA-AI

neutral

01/05/23 8:00 AM

Nasdaq : SLRX

low float

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders

RHEA-AI

neutral

12/13/22 8:01 AM

Nasdaq : SLRX

clinical triallow float

Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among eight myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who relapsed or progressed after hypomethylating agent

RHEA-AI

negative

12/13/22 8:00 AM

Nasdaq : SLRX

low float

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid ®) Synergistic activity with rituximab in DLBCL mouse model resulted in complete regressions and was superior to the approved regimen, lenalidomide

RHEA-AI

neutral

12/08/22 8:00 AM

Nasdaq : SLRX

clinical triallow float

Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in

RHEA-AI

neutral

12/01/22 8:00 AM

Nasdaq : SLRX

clinical triallow float

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

RHEA-AI

neutral

11/10/22 8:30 AM

Nasdaq : SLRX

earningslow float

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the

RHEA-AI

neutral

11/03/22 9:57 AM

Nasdaq : SLRX

low float

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abstracts

RHEA-AI

neutral

10/27/22 8:30 AM

Nasdaq : SLRX

clinical triallow float

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

SLRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitesalariuspharma.com
CeoDavid Arthur
Security nameSalarius Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees16
Tags
- Health Technology
- Pharmaceuticals: Other
- Commercial Services
- Miscellaneous Commercial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2450 Holcombe Blvd Ste J-608
StateTexas
CityHouston
Zip77021-2041
CountryUS
Phone13467720346

About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and Ewing-related sarcomas, also called FET-translocated sarcomas. Ewing sarcoma has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).